PP
ADAP

Paloma Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Paloma Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27,400
Closed -$33K – 1182
2019
Q4 		$33K Buy
+27,400
New +$29.2K ﹤0.01% 2090
2017
Q2 		– Sell
-30,000
Closed -$165K – 2121
2017
Q1 		$165K Buy
+30,000
New +$131K ﹤0.01% 1882

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paloma Partners's ADAP Position: Q1 2020 in Review

Paloma Partners sold out of Adaptimmune Therapeutics (ADAP) in Q1 2020, closing a stake of 27,400 shares — an estimated $33K sold.

Paloma Partners first reported a position in ADAP in Q1 2017 and held it in 2 quarters. The position peaked at $165K in Q1 2017. 47 funds tracked by Wall St. Rank hold ADAP as of Q1 2020.

  • Paloma Partners reported no remaining Adaptimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 27,400 Adaptimmune Therapeutics shares in Q1 2020, an estimated $33K.
  • Paloma Partners first reported a position in Adaptimmune Therapeutics in Q1 2017 and held it in 2 quarters.
  • Paloma Partners's Adaptimmune Therapeutics position peaked at $165K in Q1 2017.
  • 47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.